TrialJournal for immunotherapy of cancer2023

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.

Todd M Bauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.